Array Biopharma Inc (ARRY1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
SERVICES-MEDICAL LABORATORIES
CEO:
Ron Squarer
Employees:
298
3200 WALNUT STREET, BOULDER, CO 80301
3033816600

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Array BioPharma, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, ONT-380 (ARRY-380), ARRY-797, Ipatasertib, Motolimod, Danoprevir, ARRy-614, GDC-0994, and LOXO-101. Its drugs focuses on the treatment of cancer and inflammatory diseases. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Data derived from most recent annual or quarterly report
Market Cap 6.077 Billion Shares Outstanding126.994 Million Avg 30-day Volume 5.343 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.17
Price to Revenue22.3793 Debt to Equity0.4451 EBITDA-112.826 Million
Price to Book Value17.7753 Operating Margin-49.654199999999996 Enterprise Value5.017 Billion
Current Ratio5.699 EPS Growth0.134 Quick Ratio5.248
1 Yr BETA 1.9373 52-week High/Low 0.0 / Profit Margin-52.6416
Operating Cash Flow Growth-57.156 Altman Z-Score9.8869 Free Cash Flow to Firm -107.058 Million
View SEC Filings from ARRY1 instead.

View recent insider trading info

Funds Holding ARRY1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARRY1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2019-07-30:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-06-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-05-21:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-05-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-02-20:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2019-02-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-10-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-10-26:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-02-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ATI INVESTMENT PARENT, LLC

    BROOKFIELD ASSET MANAGEMENT INC.

    OAKTREE POWER OPPORTUNITIES FUND IV, L.P.

    OAKTREE POWER OPPORTUNITIES FUND IV (PARALLEL), L.P.

    OAKTREE ATI INVESTORS, L.P.

    OAKTREE CAPITAL MANAGEMENT LP

    OAKTREE CAPITAL GROUP, LLC

    ATLAS OCM HOLDINGS, LLC

    OAKTREE CAPITAL GROUP HOLDINGS, L.P.

    • 10% Owner
    35,713,217 2020-12-07 0

    ASHFORD ORLANDO D

    • Director
    0 2020-10-19 0

    ALSTEAD TROY

    • Director
    0 2020-10-19 0

    FUSARO JAMES MACMILLAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    0 2020-10-14 0

    JONNA PETER JOSEPH

    • Director
    0 2020-10-14 0

    BOLLAND STUART M. CHIEF OPERATIONS OFFICER

    • Officer
    0 2020-10-14 0

    FORTH JOHN BRADFORD

    • Director
    0 2020-10-14 0

    CANNOVA FRANK R.

    • Director
    0 2020-10-14 0

    CREASY LUCAS D. CHIEF TECHNOLOGY OFFICER

    • Officer
    0 2020-10-14 0

    PATEL NIPUL M. CHIEF FINANCIAL OFFICER

    • Officer
    0 2020-10-14 0

    CORIO RON P.

    • Director
    0 2020-10-14 0

    LEE JASON J.

    • Director
    0 2020-10-14 0

    MACVANE CHARLOTTE A. SEE REMARKS

    • Officer
    0 2020-10-14 0

    CHERASO JENNIFER K. CHIEF HUMAN RESOURCES OFFICER

    • Officer
    0 2020-10-14 0

    KRANTZ JEFFREY P. CHIEF COMMERCIAL OFFICER

    • Officer
    0 2020-10-14 0

    COX CARRIE SMITH

    • Director
    No longer subject to file 2019-07-30 0

    LEFKOFF KYLE

    • Director
    No longer subject to file 2019-07-30 0

    VAN LUNSEN GIL J

    • Director
    No longer subject to file 2019-07-30 0

    SHARP SHALINI

    • Director
    No longer subject to file 2019-07-30 0

    SQUARER RON CEO

    • Officer
    • Director
    No longer subject to file 2019-07-30 0

    ORWIN JOHN A

    • Director
    No longer subject to file 2019-07-30 0

    FYFE GWEN A.

    • Director
    No longer subject to file 2019-07-30 0

    BAUM CHARLES M

    • Director
    No longer subject to file 2019-07-30 0

    ROBBINS ANDREW R COO

    • Officer
    No longer subject to file 2019-07-30 0

    SACCOMANO NICHOLAS A CSO

    • Officer
    No longer subject to file 2019-07-30 0

    SANDOR VICTOR CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2019-07-30 0

    HADDOCK JASON CFO

    • Officer
    No longer subject to file 2019-07-30 0

    OLTMANS CURTIS GALE GENERAL COUNSEL

    15,021 2019-01-29 0

    MOORE JOHN R VP, GENERAL COUNSEL

    42,064 2017-04-01 0

    REDMILE GROUP, LLC

    GREEN JEREMY

    • 10% Owner
    16,658,072 2016-09-28 0

    HENAHAN MARY P. CHIEF FINANCIAL OFFICER

    0 2015-09-08 0

    SNITMAN DAVID COO AND VP, BUSINESS DEVEL.

    • Officer
    7,477 2015-03-01 0

    HORIN DAVID J INTERIM CFO

    • Officer
    0 2015-01-29 0

    CARRUTHERS MICHAEL CFO

    • Officer
    0 2014-08-18 0

    NEEDLE MICHAEL N CMO

    • Officer
    0 2014-08-18 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INVESTMENTS LLC

    BVF INC/IL

    LAMPERT MARK N

    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    No longer subject to file 2014-07-01 0

    ZABRISKIE JOHN L

    • Director
    0 2013-10-23 0

    RATCLIFFE LIAM

    • Director
    0 2013-10-23 0

    KOCH KEVIN PRESIDENT, CSO

    • Officer
    927,161 2013-07-24 0

    BULLOCK FRANCIS J

    • Director
    0 2011-10-26 0

    CONWAY ROBERT CEO

    • Officer
    • Director
    713,386 2011-10-04 0

    CARUTHERS MARVIN H

    • Director
    446,934 2011-08-16 0

    WILLIAMS DOUGLAS E

    • Director
    0 2010-11-04 0

    YATES JOHN CMO

    • Officer
    0 2007-05-14 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments